Sign In

Silvia Siegfried-Schanz

Director Investor Relations BB Biotech AG bei Bellevue Asset Management

Professional Background

Silvia Siegfried-Schanz is an accomplished investment professional with an impressive track record spanning the fields of investment analysis and healthcare. With significant experience in strategic communication and extensive knowledge in the pharmaceuticals and biotechnology sectors, Silvia currently serves as the Director of Investor Relations at BB Biotech AG, where she is responsible for effectively managing communication between the company's management and its shareholders. Her role involves engaging with investors, providing them with insights into the company’s performance, and ensuring that BB Biotech AG's strategic goals are well articulated to the investment community.

Prior to her current position at BB Biotech AG, Silvia honed her skills as an Equity Analyst at UBS Wealth Management, where she specialized in global healthcare. Her analytical skills and market insight enabled her to identify investment opportunities, providing valuable guidance to her clients in the healthcare sector. This role followed her tenure as a Financial Analyst focusing on Pharmaceuticals and Biotechnology at Bank Vontobel AG, where she gained considerable expertise in financial modeling and data analysis related to the healthcare industry.

Education and Achievements

Silvia earned her credentials as a Certified International Investment Analyst (CIIA) from the Swiss Financial Analysts Association (SFAA), solidifying her understanding of global investment strategies and capital markets. Her academic journey began at ETH Zürich, where she pursued advanced studies that laid the foundation for her career in finance and healthcare analysis.

In addition to her studies at ETH Zürich, Silvia's education includes her time at the University of Zurich, where she attended the Swiss Banking Institute, gaining insights into the complexities of banking and financial services. Her diverse academic background also features studies at esteemed institutions such as the Ecole normale supérieure de Lyon and the Albert-Ludwigs-Universität Freiburg im Breisgau, enriching her understanding of international perspectives in both finance and scientific research.

In parallel with her roles in investment, Silvia also holds a PhD in Molecular Cancer Research from ETH Zurich. Her research work in this area not only reflects her commitment to advancing medical science but also complements her investment career by grounding her analyses in a deep understanding of biotechnology and pharmaceuticals. Silvia’s blend of scientific knowledge and financial acumen makes her a unique asset in the investment community.

Achievements

Throughout her career, Silvia has accumulated notable achievements that underscore her expertise in the investment field. As a Medical Writer at Krebsliga Schweiz, she contributed significantly to healthcare communication, creating documents and materials that transform complex scientific information into accessible, patient-friendly content. This experience was pivotal in shaping her skills in communication—a crucial aspect of her current role in investor relations.

Her academic assistance roles at both the Institute for Molecular Medicine and the Max-Planck Institute for Immunology provided her with a robust foundation in scientific inquiry and research methodology. These experiences, combined with internships at renowned organizations such as Genentech and Roche Pharmaceuticals, equipped her with a comprehensive understanding of the pharmaceutical landscape and the intricacies of drug development.

Silvia's diverse background is further enriched by her analytic skills developed during her impactful tenure as an analyst in various financial institutions. Her rigorous training in scientific research and her proficiency in financial analysis converge, making her a leading professional in the intersection of finance and healthcare investment.

Silvia Siegfried-Schanz is not only a formidable figure within the investment community but also a valuable thought leader in the healthcare investment sector. Her unique combination of scientific expertise and financial insight positions her as an influential professional capable of driving informed investment decisions in the rapidly evolving biotech landscape.

Related Questions

How did Silvia Siegfried-Schanz transition from academic research to a career in investment analysis?
What strategies does Silvia Siegfried-Schanz employ to effectively communicate with investors at BB Biotech AG?
In what ways has Silvia Siegfried-Schanz’s PhD in Molecular Cancer Research influenced her work in finance?
How has Silvia's experience as an equity analyst shaped her perspective on the healthcare market?
What are some of the critical challenges Silvia Siegfried-Schanz faces in her role within investor relations?
Silvia Siegfried-Schanz
Add to my network

Location

Zurich, Switzerland